Carna Biosciences Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	579	636	1,625	1,386	2,017
Revenue Growth (YoY)	-8.96%	-60.86%	17.24%	-31.28%	78.02%
Cost of Revenue	191	171	175	171	135
Gross Profit	388	465	1,450	1,215	1,882
Selling, General & Admin	612	655	664	603	572
Research & Development	1,851	1,886	1,903	1,882	1,841
Operating Expenses	2,463	2,541	2,567	2,485	2,413
Operating Income	-2,075	-2,076	-1,117	-1,270	-531
Interest Expense	-52	-3	-4	-6	-4
Interest & Investment Income	5	14	-	-	-
Currency Exchange Gain (Loss)	-23	26	-	-	14
Other Non Operating Income (Expenses)	-1	-42	-5	-3	-3
EBT Excluding Unusual Items	-2,146	-2,081	-1,126	-1,279	-524
Asset Writedown	-24	-93	-4	-44	-9
Pretax Income	-2,170	-2,174	-1,130	-1,323	-533
Income Tax Expense	1	4	22	26	1
Net Income	-2,171	-2,178	-1,152	-1,349	-534
Net Income to Common	-2,171	-2,178	-1,152	-1,349	-534
Shares Outstanding (Basic)	19	18	17	14	13
Shares Outstanding (Diluted)	19	18	17	14	13
Shares Change (YoY)	6.71%	6.61%	23.37%	7.26%	3.22%
EPS (Basic)	-113.60	-121.61	-68.57	-99.06	-42.06
EPS (Diluted)	-113.60	-121.61	-68.57	-99.06	-42.06
Free Cash Flow	-2,168	-1,387	-1,688	-834	-1,577
Free Cash Flow Per Share	-113.44	-77.44	-100.48	-61.24	-124.22
Gross Margin	67.01%	73.11%	89.23%	87.66%	93.31%
Operating Margin	-358.38%	-326.41%	-68.74%	-91.63%	-26.33%
Profit Margin	-374.96%	-342.45%	-70.89%	-97.33%	-26.47%
Free Cash Flow Margin	-374.44%	-218.08%	-103.88%	-60.17%	-78.19%
EBITDA	-2,044	-2,045	-1,082	-1,237	-512
EBITDA Margin	-	-	-66.59%	-89.25%	-25.38%
D&A For EBITDA	31	31	35	33	19
EBIT	-2,075	-2,076	-1,117	-1,270	-531
EBIT Margin	-	-	-68.74%	-91.63%	-26.33%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.